Stockreport

Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients

KITOV PHARAMCEUTICALS HOLDINGS LTD AMERICAN DEPOS  (KTOV) 
US:NASDAQ Investor Relations: kitovpharma.com
PDF TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to ov [Read more]